This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.
This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
-
University of Alabama at Birmingham, Birmingham, Alabama, United States, 35294
University of Arizona, Phoenix, Arizona, United States, 85004
Orlando Health Cancer Institute, Orlando, Florida, United States, 32806
University of Illinois Cancer Center, Chicago, Illinois, United States, 60612
Parkview Research Center, Fort Wayne, Indiana, United States, 46845
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States, 52242
Tufts Medical Center, Boston, Massachusetts, United States, 02111
University of Michigan Health System, Ann Arbor, Michigan, United States, 48109
University of Michigan Health-West, Wyoming, Michigan, United States, 49519
University of Nebraska Medical Center, Omaha, Nebraska, United States, 68198
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Oana Danciu,
Oana Danciu, MD, PRINCIPAL_INVESTIGATOR, University of Illinois at Chicago
2027-12